NCT01843686View on ClinicalTrials.gov

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

PHASE1UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

February 28, 2018

Study Completion Date

March 31, 2018

Conditions
Acute Burns
Interventions
DEVICE

Magellan®

Autologous Platelet Rich Plasma Prepared Using the Magellan System

OTHER

Placebo Saline Gel and Usual and Customary Standard of Care

Trial Locations (3)

20010

Medstar Health Research Institute, Washington D.C.

84132

University of Utah Hospital, Salt Lake City

95817

University of California, Davis, Division of Burn Surgery, Sacramento

Sponsors

Lead Sponsor

Arteriocyte, Inc.
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Arteriocyte, Inc.

INDUSTRY

NCT01843686 - Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns | Biotech Hunter | Biotech Hunter